Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024
Rhea-AI Summary
Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, has announced it will report its second quarter 2024 financial results and provide a corporate update on August 8, 2024. The company is developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). A conference call and live audio webcast will be held at 4:30 p.m. ET on the same day.
Interested parties can join the call by dialing (877) 870 4263 (domestic) or (412) 317 0790 (international) and asking to join the Trevi Therapeutics call. A live audio webcast will be available on the company's website, with an archived replay accessible for 30 days following the event.
Positive
- Trevi Therapeutics is progressing with the development of Haduvio™ for chronic cough treatments
- The company is maintaining transparency by hosting a conference call and webcast for investors
Negative
- None.
News Market Reaction – TRVI
On the day this news was published, TRVI declined 2.52%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference call and webcast to be held at 4:30 p.m. ET
To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is a dual ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough. Parenteral nalbuphine is not scheduled by the
The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal benefit to patients. Chronic cough affects up to
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-second-quarter-2024-financial-results-and-provide-a-corporate-update-on-august-8-2024-302212091.html
SOURCE Trevi Therapeutics, Inc.
FAQ
When will Trevi Therapeutics (TRVI) report its Q2 2024 financial results?
What time is Trevi Therapeutics' (TRVI) Q2 2024 earnings call scheduled for?
What treatments is Trevi Therapeutics (TRVI) currently developing?
How can investors join Trevi Therapeutics' (TRVI) Q2 2024 earnings call?
